VRT106 plus chemo for resectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that can be removed with surgery.
- You are in good general health (able to do daily activities with little or no help).
- Your doctor expects you to live at least 6 more months.
- You have not had any other cancer treatment (like oncolytic virus therapy or chemotherapy) for your pancreatic cancer.
- You are not pregnant or breastfeeding, and you do not have a weakened immune system or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called VRT106 combined with chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.